Related Experiment Video
Updated: Sep 29, 2025

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
Clinicopathologic Factors Associated With Reversion to Normal Cognition in Patients With Mild Cognitive Impairment
Zonghua Li1, Michael G Heckman1, Takahisa Kanekiyo1
1From the Department of Neuroscience (Z.L., T.K., Y.A.M., C.-C.L., N.Z., G.B.), Division of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences (M.G.H.), Division of Behavioral Neurology (G.S.D.), and Neuroscience Graduate Program (G.B.), Mayo Clinic, Jacksonville, FL; Division of Epidemiology, Department of Quantitative Health Sciences (M.V.), and Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL.
Background And Objectives:
To identify clinicopathologic factors contributing to mild cognitive impairment (MCI) reversion to normal cognition.
Methods:
We analyzed 3 longitudinal cohorts in this study: the Mayo Clinic Study of Aging (MCSA), the Religious Orders Study and Memory and Aging Project (ROSMAP), and the National Alzheimer's Coordinating Center (NACC). Demographic characteristics and clinical outcomes were compared between patients with MCI with or without an experience of reversion to normal cognition (referred to as reverters and nonreverters, respectively). We also compared longitudinal changes in cortical thickness, glucose metabolism, and amyloid and tau load in a subcohort of reverters and nonreverters in MCSA with MRI or PET imaging information from multiple visits.
Results:
We identified 164 (56.4%) individuals in MCSA, 508 (66.8%) individuals in ROSMAP, and 280 (34.1%) individuals in NACC who experienced MCI reversion to normal cognition. Cox proportional hazards regression models showed that MCI reverters had an increased chance of being cognitively normal at the last visit in MCSA (HR 3.31, 95% CI 2.14-5.12), ROSMAP (HR 3.72, 95% CI 2.50-5.56), and NACC (HR 9.29, 95% CI 6.45-13.40) and a reduced risk of progression to dementia (HR 0.12, 95% CI 0.05-0.29 in MCSA; HR 0.41, 95% CI 0.32-0.53 in ROSMAP; and HR 0.29, 95% CI 0.21-0.40 in NACC). Compared with MCI nonreverters, reverters had better-preserved cortical thickness (β = 0.082, p <0.001) and glucose metabolism (β = 0.119, p = 0.001) and lower levels of amyloid, albeit statistically nonsignificant (β = -0.172, p = 0.090). However, no difference in tau load was found between reverters and nonreverters (β = 0.073, p = 0.24).
Discussion:
MCI reversion to normal cognition is likely attributed to better-preserved cortical structure and glucose metabolism.
Insights
Mild cognitive impairment (MCI) can revert to normal cognition, particularly in individuals with better preserved brain structure and glucose metabolism. This finding offers hope for cognitive recovery and reduced dementia risk.
Area of Science:
- Neuroscience
- Gerontology
- Clinical Neurology
Background:
- Mild cognitive impairment (MCI) is a transitional stage between normal cognition and dementia.
- Understanding factors influencing MCI reversion to normal cognition is crucial for developing interventions.
- Longitudinal studies are essential to track cognitive changes and identify predictive markers.
Purpose of the Study:
- To identify clinicopathologic factors associated with the reversion of mild cognitive impairment (MCI) to normal cognition.
- To compare cognitive outcomes and neuroimaging markers between MCI patients who revert and those who do not.
- To assess the impact of MCI reversion on the risk of dementia progression.
Main Methods:
- Analysis of three longitudinal cohorts: Mayo Clinic Study of Aging (MCSA), Religious Orders Study and Memory and Aging Project (ROSMAP), and National Alzheimer's Coordinating Center (NACC).
- Comparison of demographic characteristics and clinical outcomes between MCI reverters and non-reverters.
- Longitudinal assessment of cortical thickness, glucose metabolism, amyloid, and tau load using MRI or PET imaging in a subcohort.
Main Results:
- A significant proportion of individuals with MCI experienced reversion to normal cognition across all cohorts (34.1%–66.8%).
- MCI reverters showed a substantially increased chance of remaining cognitively normal and a reduced risk of dementia progression compared to non-reverters.
- Reverters exhibited better-preserved cortical thickness and glucose metabolism, with a trend towards lower amyloid levels, but no difference in tau load.
Conclusions:
- Reversion from mild cognitive impairment to normal cognition is a significant phenomenon observed in a substantial portion of affected individuals.
- Preserved cortical structure and glucose metabolism are key factors associated with MCI reversion.
- These findings highlight potential biomarkers and therapeutic targets for promoting cognitive recovery and preventing dementia.
More Related Videos
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
Related Concept Videos
Cognitive Development During Adulthood
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Psychological and Sociocultural Causes of Schizophrenia
Dementia
The progression of dementia is generally gradual....
Classification of Illness
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe...
Revisionist Views of Adolescent and Adult Cognition